Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].

Gong H, Yuan Y, Li Y, Zhang H, Li Y, Li W, Wang P, Shi R, Liu C, Cui L, Liu H, Chen J.

Zhongguo Fei Ai Za Zhi. 2019 May 20;22(5):255-263. doi: 10.3779/j.issn.1009-3419.2019.05.01. Chinese.

2.

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Wu M, Yuan Y, Pan YY, Zhang Y.

Mol Med Rep. 2014 Aug;10(2):931-8. doi: 10.3892/mmr.2014.2243. Epub 2014 May 16.

PMID:
24840891
3.

[Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].

Ju LX, Zhou CC, Tang L, Zhao YM, Yang XJ, Su B, Meng SY, Li W, Yan LH, Ding YM.

Zhonghua Jie He He Hu Xi Za Zhi. 2010 May;33(5):354-8. Chinese.

PMID:
20646614
4.

γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.

Xie M, He J, He C, Wei S.

J Cell Biochem. 2015 Jun;116(6):1019-27. doi: 10.1002/jcb.25056.

PMID:
25561332
5.

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.

Song YA, Ma T, Zhang XY, Cheng XS, Olajuyin AM, Sun ZF, Zhang XJ.

Cancer Cell Int. 2019 May 2;19:117. doi: 10.1186/s12935-019-0836-8. eCollection 2019.

6.

[Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].

Yang XB, Chen X, Wu WY, Long SQ, Chen SM, Han SW.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016 Nov;36(11):1340-1344. Chinese.

PMID:
30641628
7.

[Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].

Fang X, Gu P, Zhou CC, Ren SX, Luo BF, Zeng Y, Wu YJ, Zhao YM, Zhu XY, Yi XH.

Zhonghua Bing Li Xue Za Zhi. 2013 Jul;42(7):455-9. doi: 10.3760/cma.j.issn.0529-5807.2013.07.006. Chinese.

PMID:
24246864
8.

PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.

Zhou J, Kwak KJ, Wu Z, Yang D, Li J, Chang M, Song Y, Zeng H, Lee LJ, Hu J, Bai C.

Cell Physiol Biochem. 2018;47(5):1909-1924. doi: 10.1159/000491071. Epub 2018 Jun 29.

9.

Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.

Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC.

Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. doi: 10.1164/rccm.201009-1440OC. Epub 2010 Oct 29.

PMID:
21037017
10.
11.
12.

Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.

Wang B, Jiang H, Wang L, Chen X, Wu K, Zhang S, Ma S, Xia B.

Oncol Lett. 2017 May;13(5):3494-3500. doi: 10.3892/ol.2017.5878. Epub 2017 Mar 20.

13.

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.

Liu JT, Li WC, Gao S, Wang F, Li XQ, Yu HQ, Fan LL, Wei W, Wang H, Sun GP.

Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.

PMID:
25979647
14.

Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.

Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.

Adv Med Sci. 2011;56(2):275-84. doi: 10.2478/v10039-011-0043-x.

PMID:
22037177
15.

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Ju L, Zhou C, Li W, Yan L.

J Cell Biochem. 2010 Dec 15;111(6):1565-74. doi: 10.1002/jcb.22888.

PMID:
21053345
16.

β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.

Fang X, Gu P, Zhou C, Liang A, Ren S, Liu F, Zeng Y, Wu Y, Zhao Y, Huang B, Zhang Z, Yi X.

Pulm Pharmacol Ther. 2014 Jun;28(1):41-8. doi: 10.1016/j.pupt.2013.05.005. Epub 2013 May 23.

PMID:
23707949
17.
18.

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S.

Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15.

PMID:
22985911
19.

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF.

Oncol Rep. 2013 May;29(5):1975-82. doi: 10.3892/or.2013.2298. Epub 2013 Feb 21.

PMID:
23440266
20.

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.

Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, Wang YY.

BMC Cancer. 2016 Jul 18;16:491. doi: 10.1186/s12885-016-2519-3.

Supplemental Content

Support Center